Go Pro
→ Bezos… DOOMED (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BOPH
Bohai Pharmaceuticals Group
$0.00
$0.00
$0.00
▼
$0.00
$20K1.7830,425 shs50,000 shs
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$0.00
$0.03
$0.00
▼
$0.11
$27K-0.5329,856 shs58,418 shs
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$0.00
-12.5%		$0.00
$0.00
▼
$0.30
$29K-9.0258,843 shs2,591 shs
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
$0.00
$0.00
$0.00
▼
$0.20
$10K-76.446,025 shs1,610 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BOPH
Bohai Pharmaceuticals Group
0.00%0.00%0.00%0.00%0.00%
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00%+150.00%-98.08%-98.45%-99.27%
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
0.00%+14.29%-38.46%-86.44%-99.72%
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
0.00%0.00%0.00%-99.49%-99.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BOPH
Bohai Pharmaceuticals Group
$0.00
$0.00
$0.00
▼
$0.00
$20K1.7830,425 shs50,000 shs
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$0.00
$0.03
$0.00
▼
$0.11
$27K-0.5329,856 shs58,418 shs
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$0.00
-12.5%		$0.00
$0.00
▼
$0.30
$29K-9.0258,843 shs2,591 shs
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
$0.00
$0.00
$0.00
▼
$0.20
$10K-76.446,025 shs1,610 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BOPH
Bohai Pharmaceuticals Group
0.00%0.00%0.00%0.00%0.00%
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00%+150.00%-98.08%-98.45%-99.27%
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
0.00%+14.29%-38.46%-86.44%-99.72%
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
0.00%0.00%0.00%-99.49%-99.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BOPH
Bohai Pharmaceuticals Group
0.00
N/AN/AN/A
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00
N/AN/AN/A
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
1.00
SellN/AN/A
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BOPH
Bohai Pharmaceuticals Group
N/AN/AN/AN/AN/AN/A
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/A$0.71 per shareN/A
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$10.77M0.00N/AN/A($0.67) per share0.00
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BOPH
Bohai Pharmaceuticals Group
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-$16.08M-$1.09N/AN/AN/AN/A-2,842.40%-337.48%11/12/2026 (Estimated)
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
-$60.48M$0.730.00N/AN/A-254.28%N/A-192.17%11/5/2026 (Estimated)
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
-$56.93M-$0.30N/AN/AN/AN/AN/AN/A11/11/2026 (Estimated)
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BOPH
Bohai Pharmaceuticals Group
N/AN/AN/AN/AN/A
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/AN/A
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
N/AN/AN/AN/AN/A
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BOPH
Bohai Pharmaceuticals Group
N/AN/AN/A
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/A
0.86
0.86
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
N/A
0.48
0.48
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
BOPH
Bohai Pharmaceuticals Group
N/A
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
5.74%
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
44.27%
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
82.95%

Insider Ownership

CompanyInsider Ownership
BOPH
Bohai Pharmaceuticals Group
N/A
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.72%
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
6.90%
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
64.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
BOPH
Bohai Pharmaceuticals Group
N/A19.52 millionN/ANot Optionable
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
1053.90 million5.73 millionNo Data
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
2041.85 million38.91 millionNo Data
Vaxxinity, Inc. stock logo
VAXX
Vaxxinity
90126.75 million45.55 millionNot Optionable

Recent News About These Companies

Vaxxinity stock targets neurological disease programs
September 24, 2026  |  ad-hoc-news.deA
Vaxxinity stock holds at USD 0.00 amid thin market data
September 22, 2026  |  ad-hoc-news.deA
Vaxxinity stock holds at penny level as investors watch recent vaccine data
September 18, 2026  |  ad-hoc-news.deA
Vaxxinity Inc.
May 25, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/vaxx/financials
Brain health
October 24, 2024  |  newsweek.comN
Treatment Trials in Alzheimer's Disease
September 30, 2024  |  msn.comhttps://www.msn.com/en-au/health/other/treatment-trials-in-alzheimer-s-disease/ar-BB1mwHGY
Is Vaxxinity Inc (VAXX) Stock a Good Investment?
September 19, 2024  |  aaii.comA
Congress makes $4.5 trading stocks in a day; Here's the biggest winners
July 4, 2024  |  finbold.comF
Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine
June 20, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/06/20/2901487/0/en/vaxxinity-ub-312-parkinson-s-trial-results-published-in-nature-medicine.html
Why Is Vaxxinity (VAXX) Stock Up 39% Today?
May 3, 2024  |  investorplace.comhttps://investorplace.com/2024/05/why-is-vaxxinity-vaxx-stock-up-39-today/
Why Is Vaxxinity (VAXX) Stock Down 58% Today?
April 22, 2024  |  investorplace.comhttps://investorplace.com/2024/04/why-is-vaxxinity-vaxx-stock-down-58-today/
Vaxxinity Plans to Delist Shares From Nasdaq
April 19, 2024  |  marketwatch.comhttps://www.marketwatch.com/story/vaxxinity-plans-to-delist-shares-from-nasdaq-0b4e6e00
Vaxxinity Issues Shareholder Letter
April 19, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/04/19/2866409/0/en/vaxxinity-issues-shareholder-letter.html
Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock
April 19, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/04/19/2866373/0/en/vaxxinity-announces-intention-to-voluntarily-delist-and-deregister-its-class-a-common-stock.html
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
March 28, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/03/28/2854092/0/en/vaxxinity-to-present-clinical-data-at-the-annual-academy-of-neurology-2024-annual-meeting.html
VAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023
March 27, 2024  |  investorplace.comhttps://investorplace.com/earning-results/2024/03/vaxx-stock-earnings-vaxxinity-for-q4-of-2023/?cc=marketbeat&cp=pdtk
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
March 27, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/03/27/2853637/0/en/vaxxinity-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-corporate-updates.html
Vaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol Levels
February 15, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/vaxxinity-heart-health-innovation-reduces-162929693.html?.tsrc=rss
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
February 15, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/vaxxinity-cholesterol-vaccine-candidate-successfully-130000609.html?.tsrc=rss
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024
February 13, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/vaxxinity-present-clinical-preclinical-pipeline-130000495.html?.tsrc=rss

New MarketBeat Followers Over Time

Bohai Pharmaceuticals Group OTCMKTS:BOPH

$0.0010 0.00 (0.00%)
As of 03/11/2019

Bohai Pharmaceuticals Group, Inc. engages in the production, manufacture, and distribution of herbal pharmaceuticals based on traditional Chinese medicine. Its products include lung nourishing syrup, tongbi capsules, tongbi tablets, zhuangyuanshenhailong medicinal wine, bazhenyimu cream, fangfengtongsheng granule, and zhengxintai capsules. The company was founded on January 9, 2008 and is headquartered in Yantai, China.

Bio-Path stock logo

Bio-Path NASDAQ:BPTH

$0.0005 0.00 (0.00%)
As of 09/25/2026 02:23 PM Eastern

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

Carisma Therapeutics stock logo

Carisma Therapeutics NASDAQ:CARM

$0.0007 0.00 (-12.50%)
As of 02:45 PM Eastern

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Vaxxinity stock logo

Vaxxinity OTCMKTS:VAXX

$0.0001 0.00 (0.00%)
As of 01:43 PM Eastern

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas